Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

作者：Johanna T. W. Wigman, Ann Ee Ching, Yoonho Chung, Habiballah Rahimi-Eichi, Erlend Lane, Carsten Langholm, Aditya Vaidyam, Andrew Jin Soo Byun, Anastasia Haidar, Jessica Hartmann, Ángela Núñez, Dominic Dwyer, Adibah Amani Nasarudin, Owen Borders, Isabelle Scott, Zailyn Tamayo, Priya Matneja, Kang Ik K. Cho, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Díaz‐Caneja, Lauren M. Ellman, Paolo Fusar‐Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz‐Ilankovic, Matcheri S. Keshavan, Sung‐Wan Kim, Nikolaos Koutsouleris, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesús Pérez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai Shah, Steven M. Silverstein, Stefan Smesny, Walid Yassin, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Phillip Wolff, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Laura M. Rowland, Simon D’Alfonso, Ofer Pasternak, Sylvain Bouix, Patrick D. McGorry, René S. Kahn, John M. Kane, Carrie E. Bearden, Scott W. Woods, Martha E. Shenton, Barnaby Nelson, Justin T. Baker, John Torous · 发表于：Schizophrenia · 年份：2025 · DOI：10.1038/s41537-025-00599-w · 被引用次数：11 · 研究领域：Digital Mental Health Interventions、Mental Health Research Topics、Treatment of Major Depression

Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital mea...